Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease

Rivastigmine (or Exelon) is a cholinesterase inhibitor, currently used as a symptomatic treatment for mild-to-moderate Alzheimer’s disease (AD). Amyloid-β peptide (Aβ) generated from its precursor protein (APP) by β-secretase (or BACE1) and γ-secretase endoproteolysis. Alternative APP cleavage by α-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Balmiki, Maloney, Bryan, Sambamurti, Kumar, Karnati, Hanuma K., Nelson, Peter T., Greig, Nigel H., Lahiri, Debomoy K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026402/
https://www.ncbi.nlm.nih.gov/pubmed/32066688
http://dx.doi.org/10.1038/s41398-020-0709-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026402/
https://www.ncbi.nlm.nih.gov/pubmed/32066688
http://dx.doi.org/10.1038/s41398-020-0709-x

Ejemplares similares